Shares of Qiagen QGEN quite in after-market trading after the company reported Q1 results.
Quarterly Results
Earnings per share were up 94.12% year over year to $0.66, which beat the estimate of $0.63.
Revenue of $567,206,000 higher by 52.43% from the same period last year, which beat the estimate of $557,500,000.
Recent Stock Performance
Company's 52-week high was at $59.00
Company's 52-week low was at $41.36
Price action over last quarter: down 13.42%
Company Overview
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates over 85% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (44% of 2020 sales), followed by EMEA (36%) and Asia-Pacific (19%).
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
